MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity used for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of Treprostinil (Tyvaso DPI) used for the treatment of pulmonary arterial hypertension; and Thirona Bio to evaluate the therapeutic potential of TGF-Ã inhibitor for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
IPO Year: 2004
Exchange: NASDAQ
Website: mannkindcorp.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/16/2025 | $9.00 | Buy | H.C. Wainwright |
| 4/10/2025 | $12.00 | Outperform | Mizuho |
| 2/10/2025 | $11.00 | Outperform | Wedbush |
| 12/20/2024 | $9.00 | Overweight | Wells Fargo |
| 12/19/2024 | $7.00 → $10.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 9/9/2024 | $7.00 → $8.00 | Outperform | Leerink Partners |
| 6/13/2024 | $8.00 | Buy | Rodman & Renshaw |
| 10/10/2023 | $10.00 | Outperform | Wedbush |
| 2/28/2022 | $6.50 → $6.00 | Buy | HC Wainwright & Co. |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
H.C. Wainwright resumed coverage of Mannkind with a rating of Buy and set a new price target of $9.00
Mizuho initiated coverage of Mannkind with a rating of Outperform and set a new price target of $12.00
Wedbush initiated coverage of Mannkind with a rating of Outperform and set a new price target of $11.00
Wells Fargo initiated coverage of Mannkind with a rating of Overweight and set a new price target of $9.00
RBC Capital Mkts upgraded Mannkind from Sector Perform to Outperform and set a new price target of $10.00 from $7.00 previously
Leerink Partners resumed coverage of Mannkind with a rating of Outperform and set a new price target of $8.00 from $7.00 previously
Rodman & Renshaw initiated coverage of Mannkind with a rating of Buy and set a new price target of $8.00
Wedbush initiated coverage of Mannkind with a rating of Outperform and set a new price target of $10.00
HC Wainwright & Co. reiterated coverage of MannKind with a rating of Buy and set a new price target of $6.00 from $6.50 previously
RBC Capital initiated coverage of MannKind with a rating of Sector Perform and set a new price target of $5.00
Fastest customizable press release news feed in the world
Strengthens MannKind's capital structure with flexible, long-term, non-dilutive fundingMannKind to receive $75 million in cash at closing DANBURY, Conn. and WESTLAKE VILLAGE, Calif. and NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, and funds managed by Blackstone ("Blackstone") today announced that they have entered into an up to $500 million strategic financing agreement. The financing agreement provides MannKind with non-dilutive capital to advance its short- and long-term growth strategies
2Q 2025 revenues of $76.5M, +6% v. 2Q 2024YTD 2025 revenues of $154.9M, +12% v. YTD 2024Advanced pipeline: Submitted sBLA for Afrezza® in pediatric populationMNKD-101: NTM global Phase 3 trial (ICoN-1) enrollment ahead of scheduleMNKD-201: Plan to initiate Phase 2 clinical trial for IPF by YE 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the second quarter 2025 and provided a business update. "The submission of our supplemental Biologics License Application (sBLA) for Afrezza in pediatric patients is a meaningful milestone for MannKind and people living with diabetes," said Mi
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), announced today that its second quarter 2025 financial results will be released before market open on August 6, 2025. MannKind will host a webcast beginning at 9:00 a.m. Eastern Time to discuss the financial results and provide a business update. The webcast will be accessible via a link on MannKind's website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 24 hours following the call and be accessible for approximately 90 days. About MannKindMannKind Corporation (NASDAQ:MNKD) focuses on the developme
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, will showcase inhaled insulin at the American Diabetes Association's (ADA) 85th Scientific Sessions from June 20-23 in Chicago. Dr. Michael J. Haller, Professor and Chief of Pediatric Endocrinology at the University of Florida, will present the results from the randomized period of the INHALE-1 clinical trial during a "Future Ready" symposium. Dr. Haller is the Chair for MannKind's Phase 3 INHALE-1 study of A
WESTLAKE VILLAGE, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will team up with NTT INDYCAR SERIES driver Conor Daly, who is living with Type 1 diabetes (T1D) for a one-of-a-kind experience with Detroit area youth and families during the week of the Chevrolet Detroit Grand Prix in downtown Detroit. Daly will share his personal story of being diagnosed with diabetes as a teen and how he does not let it keep him from living life without limits. The former karting champion will also provide some karting tips and then race go-karts to identify the Fastest 6. Daly was first diagnosed with diabetes at the age of 14, and today is the only known U.S. professional r
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced its participation at the upcoming investor conferences. MannKind's Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will share updates during the following investor conferences, both being held in New York City: RBC Capital Markets 2025 Global Annual Healthcare Conference Tuesday, May 20, 8:00 a.m. ET Jefferies Global Healthcare Conference Thursday, June 5,
Conference call to provide corporate updates today at 9:00 am ET 1Q 2025 revenues of $78M, +18% v. 1Q 20241Q 2025 net income of $13M, + 24% v. 1Q 20241Q 2025 non-GAAP net income of $22M, +43% v. 1Q 2024Advanced pipeline: Expect to submit sBLA for Afrezza® in pediatric patients in mid-2025MNKD-101: NTM global Phase 3 trial enrollment on track for interim analysisMNKD-201: Expect to continue to next phase of global development in 2H 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the first quarter 2025 and provided a business update. "The first quarter was marked by strong y
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), announced today that its first quarter 2025 financial results will be released before market open on May 8, 2025. MannKind will host a webcast beginning at 9:00 a.m. Eastern Time to discuss the financial results and provide a business update. Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will participate in the conference call from MannKind. The webcast will be accessible via a link on MannKind's website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 2
Daly to showcase striking "Tired of Pricks?" livery for JHR at Acura Long Beach Grand Prix, Sunday, April 13Indiana native is the only known U.S. pro racing driver competing full-time with T1D WESTLAKE VILLAGE, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, announced today a continued partnership with Juncos Hollinger Racing (JHR) driver Conor Daly for the 2025 NTT INDYCAR Series season. Daly, who was diagnosed with diabetes at age 14, is the only known U.S. pro racing driver competing full-t
Five presentations affirm positive outcomes utilizing inhaled insulinAn sNDA filing for Afrezza in pediatric population anticipated in 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, will showcase data from recent studies of inhaled insulin across five presentations at the 18th International Conference on Advanced Technologies and Treatments for Diabetes to be held March 19-22 in Amsterdam. "Data from both the INHALE-1 pediatric and INHALE-3 adult studi
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - MANNKIND CORP (0000899460) (Issuer)
4 - MANNKIND CORP (0000899460) (Issuer)
4 - MANNKIND CORP (0000899460) (Issuer)
4 - MANNKIND CORP (0000899460) (Issuer)
4 - MANNKIND CORP (0000899460) (Issuer)
4 - MANNKIND CORP (0000899460) (Issuer)
4 - MANNKIND CORP (0000899460) (Issuer)
4 - MANNKIND CORP (0000899460) (Issuer)
4 - MANNKIND CORP (0000899460) (Issuer)
4 - MANNKIND CORP (0000899460) (Issuer)
10-Q - MANNKIND CORP (0000899460) (Filer)
8-K - MANNKIND CORP (0000899460) (Filer)
8-K - MANNKIND CORP (0000899460) (Filer)
8-K - MANNKIND CORP (0000899460) (Filer)
144 - MANNKIND CORP (0000899460) (Subject)
10-Q - MANNKIND CORP (0000899460) (Filer)
8-K - MANNKIND CORP (0000899460) (Filer)
DEFA14A - MANNKIND CORP (0000899460) (Filer)
DEF 14A - MANNKIND CORP (0000899460) (Filer)
S-3ASR - MANNKIND CORP (0000899460) (Filer)
Live Leadership Updates
Live finance-specific insights
MannKind purchased an additional convertible note issued by Thirona BioNonclinical PD study of MNKD-501 planned, with results anticipated in 2Q 2022MannKind's CEO appointed as a member of the Thirona board of directors DANBURY, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced that has extended its collaboration with Thirona Bio, Inc. ("Thirona") with the purchase of a second convertible note issued by Thirona, and the appointment of Michael Castagna, PharmD as a member of the Thirona board of directors.
2Q 2025 revenues of $76.5M, +6% v. 2Q 2024YTD 2025 revenues of $154.9M, +12% v. YTD 2024Advanced pipeline: Submitted sBLA for Afrezza® in pediatric populationMNKD-101: NTM global Phase 3 trial (ICoN-1) enrollment ahead of scheduleMNKD-201: Plan to initiate Phase 2 clinical trial for IPF by YE 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the second quarter 2025 and provided a business update. "The submission of our supplemental Biologics License Application (sBLA) for Afrezza in pediatric patients is a meaningful milestone for MannKind and people living with diabetes," said Mi
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), announced today that its second quarter 2025 financial results will be released before market open on August 6, 2025. MannKind will host a webcast beginning at 9:00 a.m. Eastern Time to discuss the financial results and provide a business update. The webcast will be accessible via a link on MannKind's website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 24 hours following the call and be accessible for approximately 90 days. About MannKindMannKind Corporation (NASDAQ:MNKD) focuses on the developme
Conference call to provide corporate updates today at 9:00 am ET 1Q 2025 revenues of $78M, +18% v. 1Q 20241Q 2025 net income of $13M, + 24% v. 1Q 20241Q 2025 non-GAAP net income of $22M, +43% v. 1Q 2024Advanced pipeline: Expect to submit sBLA for Afrezza® in pediatric patients in mid-2025MNKD-101: NTM global Phase 3 trial enrollment on track for interim analysisMNKD-201: Expect to continue to next phase of global development in 2H 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the first quarter 2025 and provided a business update. "The first quarter was marked by strong y
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), announced today that its first quarter 2025 financial results will be released before market open on May 8, 2025. MannKind will host a webcast beginning at 9:00 a.m. Eastern Time to discuss the financial results and provide a business update. Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will participate in the conference call from MannKind. The webcast will be accessible via a link on MannKind's website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 2
2024 revenues of $286M, +43% v. 2023; 4Q 2024 revenues of $77M, +31% v. 4Q 20232024 net income of $28M; Non-GAAP net income of $68M 4Q 2024 net income of $7M; Non-GAAP net income of $23MReduced debt principal by $236M; remaining convertible debt of $36MYear-end 2024 cash, cash equivalents and investments of $203MAdvanced pipeline: Reported primary endpoint of INHALE-1 for Afrezza in pediatricsProgressed MNKD-101 to Global Phase 3Completed Phase 1 of MNKD-201 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter and year ended December 31, 2024, and provided a business update. "Th
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), will release its 2024 fourth quarter and full year financial results after market close on Wednesday, February 26, 2025. MannKind will host a webcast beginning at 4:30 p.m. Eastern Time to discuss the financial results and provide a business update. Participating in the conference call from MannKind will be Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss. The webcast will be accessible via a link on MannKind's website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same locatio
Company plans to meet with FDA regarding potential sNDA submission in 1H 2025Call planned today at 8:30 a.m. (ET) to discuss company's diabetes program progression DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced six-month results from its Phase 3 INHALE-1 study of Afrezza (insulin human) Inhalation Powder in children and adolescents (aged 4-17 years of age). MannKind expects to submit a request for a supplemental new drug application (sNDA) meeting with
Conference Call to Begin Today at 4:30 p.m. (ET) 3Q 2024 Total revenues of $70M; +37% vs. 3Q 2023YTD 2024 Total revenues of $209M; +49% vs. YTD 2023YTD 2024 Net income of $20 million; Non-GAAP net income of $45 millionOrphan lung disease studies proceeding as planned MNKD-101 Phase 3 clinical trial expands globallyMNKD-201 Phase 1 successfully completed; Plan to meet with FDA in 1H 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter ended September 30, 2024. "Our business demonstrated double-digit revenue growth compared to last year, led by Tyvaso DPI revenues,"
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), announced today that its third quarter 2024 financial results will be released after market close on Thursday, November 7, 2024. MannKind will host a webcast beginning at 4:30 p.m. Eastern Time to discuss the quarterly results and provide a business update. Participating in the conference call from MannKind will be Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss. The webcast will be accessible via a link on MannKind's website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same
2Q 2024 Total revenues of $72M; +49% vs. 2Q 2023YTD 2024 Total revenues of $139M; +55% vs. YTD 2023YTD 2024 Net income of $9 million; Non-GAAP net income of $29 millionAdvances two orphan lung programs to human studies MNKD-101 Phase 3 clinical trial activities initiatedMNKD-201 Phase 1 clinical trial on schedule to read out 4Q 2024 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter ended June 30, 2024. "We achieved our ninth consecutive quarter of revenue growth and are approaching an annual revenue run rate of over $275 million based on the first half of 2024," said M
This live feed shows all institutional transactions in real time.
SC 13G/A - MANNKIND CORP (0000899460) (Subject)
SC 13G/A - MANNKIND CORP (0000899460) (Subject)
SC 13G/A - MANNKIND CORP (0000899460) (Subject)
SC 13G/A - MANNKIND CORP (0000899460) (Subject)
SC 13G - MANNKIND CORP (0000899460) (Subject)
SC 13G/A - MANNKIND CORP (0000899460) (Subject)
SC 13G - MANNKIND CORP (0000899460) (Subject)